2014 Журнал "Почки" №4 (6)

Ôàðìàêîëîã³÷íà åíöèêëîïåä³ÿ / Pharmacological Encyclopedia
15. Kirch W., Hutt H.J., Plinitz V. The influence of renal function
on clinical pharmacokinetics of moxonidine // Clin. Pharmacokinet.
1988 Oct; 15 (4): 245-53.
16. Krespi P.G., Makris T.K., Hatzizacharias A.N. et al. Moxonidine
effect on microalbuminuria, thrombomodulin, and plasminogen
activator inhibitor-1 levels in patients with essential hypertension //
Cardiovasc. Drugs Ther. 1998 Oct; 12: 463-7.
17. Doumas M.N., Douma S.N., Petidis K.M. et al. Different effects
of losartan and moxonidine on endothelial function during sympathetic
activation in essential hypertension // J. Clin. Hypertens.
(Greenwich) 2004 Dec; 6 (12): 682-9.
18. Martina B., Surber C., Jakobi C. et al. Effect of moxonidine
and cilazapril on microcirculation as assessed by finger nailfold capillaroscopy
in mild-to-moderate hypertension // Angiology 1998 Nov;
49: 897-901.
19. Farsang C., Finta E., Kerkovits L. et al. Moxonidine possibly
inhibits angiotensin converting enzyme inhibitor (ACEi)-induced
cough in patients with essential hypertension: a multicentre, open pilot
study [abstract no. P2.216] // J. Hypertens. 2003 Jun; 21 Suppl. 4:
183.
20. Troussov V., Acsenov C. Moxonidine (Phisiotens) in treatment
of hypertension in elderly patients with type 2 diabetes meltinus
[abstract no. 2543] // Diabetes Metab. 2003 Aug; 29 (4 Suppl.):
314.
21. Aparina T., Britov A., Gomazkov O. Effects of enalapril and
moxonidine on left ventricular hypertrophy in relation to insulin resistance
in hypertensive patients [abstract no. P1.198] // J. Hypertens.
2003 Jun; 21 Suppl. 4: 75.
22. Reznik L., Koval S., Koval D. et al. The effects of moxonidine
long-term monotherapy on endothelial vasoactive factors in patients
with hypertension [abstract no. 99] // J. Hypertens. 2003 Jun;
21 Suppl. 4: 336.
23. Sanjuliani A.F., Genelhu de Abreu V., Ueleres Braga J. et al.
Effects of moxonidine on the sympathetic nervous system, blood pressure,
plasma renin activity, plasma aldosterone, leptin, and metabolic
profile in obese hypertensive patients // J. Clin. Basic. Cardiol. 2004;
7: 19-25.
24. Orynchak M.A., Neyko E.M., Chovganyuk O.S. Role of moxonidine
in insulin secretion and endothelial dysfunction in the patients
with insulin resistance [abstract no. P-538] // Am. J. Hypertens.
2005 May 2; 18 (5): 202-3.
25. Moxonidine improves glycaemic control in mildly hypertensive,
overweight patients: a comparison with metformin. Hannover:
Solvay Pharmaceuticals, 2005. (Data on file)
26. Haenni A., Lithell H. Moxonidine improves insulin sensitivity
in insulin-resistant hypertensives // J. Hypertens. Suppl. 1999;
17 Suppl. 3: S29-35.
27. Kaaja R., Manhem K., Tuomilehto J. Treatment of postmenopausal
hypertension with moxonidine, a selective imidazoline receptor
agonist // Int. J. Clin. Pract. 2004 Mar; Suppl. 139: 26-32.
28. Jacob S., Klimm H.J., Rett K. et al. Effects of moxonidine vs.
metoprolol on blood pressure and metabolic control in hypertensive
subjects with type 2 diabetes // Exp. Clin. Endocrinol. Diabetes 2004
Jun; 112 (6): 315-22.
29. Strojek K., Grzeszczak W., Gоrska J. et al. Lowering of microalbuminuria
in diabetic patients by a sympathicoplegic agent: novel
approach to prevent progression of diabetic nephropathy // J. Am.
Soc. Nephrol. 2001 Mar; 12: 602-5.
30. Neumann J., Ligtenberg G., Oey L. et al. Moxonidine normalizes
sympathetic hyperactivity in patients with eprosartan-treated
chronic renal failure // J. Am. Soc. Nephrol. 2004 Nov; 15 (11):
2902-7.
31. Vonend O., Marsalek P., Russ H. et al. Moxonidine treatment
of hypertensive patients with advanced renal failure // J. Hypertens.
2003 Sep; 21 (9): 1709-17.
32. He M.M., Abraham T.L., Lindsay T.J. et al. Metabolism and
disposition of the antihypertensive agent moxonidine in humans //
Drug Metab. Dispos. 2003 Mar; 31 (3): 334-42.
33. Wise S.D., Chan C., Schaefer H.G. et al. Quinidine does not
affect the renal clearance of moxonidine // Br. J. Clin. Pharmacol.
2002 Sep; 54: 251-4.
34. Pinthong D., Songsermsakul P., Rattanachamnong P. et al.
The effects of imidazoline agents on the aggregation of human platelets
// J. Pharm. Pharmacol. 2004 Feb; 56 (2): 213-20.
35. Wenzel R.R., Mitchell A., Siffert W. et al. The I 1
-imidazoline
agonist moxonidine decreases sympathetic tone under physical and
mental stress // Br. J. Clin. Pharmacol. 2004 May; 57 (5): 545-51.
36. El-Ayoubi R., Menaouar A., Gutkowska J. et al. Urinary responses
to acute moxonidine are inhibited by natriuretic peptide receptor
antagonist // Br. J. Pharmacol. 2005 May; 45 (1): 50-6.
37. Cao C., Kang C.W., Kim S.Z. et al. Augmentation of moxonidine-induced
increase in ANP release by atrial hypertrophy // Am. J.
Physiol. Heart Circ. Physiol. 2004; 287 (1): H150-6.
38. Moreira T.S., Takakura A.C., Menani J.V. et al. Central
blockade of nitric oxide synthesis reduces moxonidine-induced hypotension
// Br. J. Pharmacol. 2004 Jun; 142 (4): 765-71.
39. Solvay Healthcare Limited. Physiotens tablets 200, 300 & 400
micrograms: summary of product characteristics [online]. Available
from URL: http://emc.medicines.org.uk [Accessed 2005 Jun 13].
40. Levy B.I. The importance of microcirculation and tissue perfusion
in hypertension [in French] // Curr. Med. Res. Opin. 2005;
21 Suppl. 5: S1-6.
41. Sleight P. The sympathetic nervous system in hypertension:
differing effects of drug treatment // Eur. Heart J. 1998 Jun; 19 Suppl.
F: 39-44.
42. Grundy S.M., Cleeman J.I., Daniels S.R. et al. Diagnosis and
management of the metabolic syndrome: an American Heart Association/National
Heart, Lung and Blood Institute scientific statement //
Circulation 2005 Sep; 112 (17): 2735-52.
43. Mogensen C.E. New treatment guidelines for a patient with
diabetes and hypertension // J. Hypertens. Suppl. 2003 Mar; 21
Suppl. 1: S25-30.
44. Abellan J., Leal M., Hernandez-Menarguez F. et al. Efficacy
of moxonidine in the treatment of hypertension in obese, noncontrolled
hypertensive patients // Kidney Int. Suppl. 2005 Jan; 67 Suppl. 93:
S20-4.
45. Sharma A.M., Wagner T., Marsalek P. Moxonidine in the
treatment of overweight and obese patients with the metabolic syndrome:
a postmarketing surveillance study // J. Hum. Hypertens. 2004
Sep; 18 (9): 669-75.
46. Frei M., Kuster L., Gardosch von Krosigk P.P. et al. Moxonidine
and hydrochlorothiazide in combination: a synergistic antihypertensive
effect // J. Cardiovasc. Pharmacol. 1994; 24 Suppl. 1: 25-8.
47. Kuppers H.E., Jager B.A., Luszick J.H. et al. Placebo-controlled
comparison of the efficacy and tolerability of once-daily moxonidine
and enalapril in mild-to-moderate essential hypertension //
J. Hypertens. 1997 Jan; 15: 93-7.
48. Prichard B.N.C., Jаger B.A., Luszick J.H. et al. Placebo-controlled
comparison of the efficacy and tolerability of once-daily moxonidine
and enalapril in mild to moderate essential hypertension //
Blood Press. 2002; 11 (3): 166-72.
49. Prichard B.N.C., Kuster L.J., Hughes P.R. et al. Dose relation
of blood pressure reduction with moxonidine: findings from three
placebo-and active-controlled randomized studies // J. Clin. Basic.
Cardiol. 2003; 6: 49-51.
50. Camilleri G., Portal B., Quiniou G. et al. Comparison of the
antihypertensive efficacy of and tolerance to two imidazoline receptor
agonists: moxonidine and rilmenidine in monotherapy [in French] //
Am. Cardiol. Angeiol. (Paris) 2001 Apr; 50 (3): 169-74.
51. Prichard B.N.C., Simmons R., Rooks M.J. et al. A doubleblind
comparison of moxomidine and atenolol in the management of
patients with milt-to-moderate hypertension // J. Cardiovasc. Pharmacol.
1992; 20 Suppl. 4: S45-9.
52. Wolf R. The treatment of hypertensive patients at calcium antagonist
or moxonidine: a comparison // J. Cardiovasc. Pharmacol.
1992; 20 Suppl. 4: S42-4.
53. Feuring M., Cassel W., Thun B. et al. Moxonidine and
ramipril in patients with hypertension and obstructive pulmonary disease
// Clin. Drug Invest. 2000 Jul; 20: 19-24.
54. Plinitz V. Comparison of moxonidine and clonidine HCl in
treating patients with hypertension // J. Clin. Pharmacol. 1987 Jan;
27 (1): 46-51.
80
Ïî÷êè, ISSN 2307-1257 ¹ 4 (6) • 2013